β2-adrenoceptor agonists are the mainstay for the acute symptomatic treatment of asthma
and provide effective bronchoprotection to a wide range of bronchoconstrictor agents …

Background and aim Recently, β-blockers have been suggested as a potential maintenance
treatment option for asthma. The aim of this review is to provide an overview of the current …

Introduction: Patients with asthma often have important co-morbidities which reduce the
likelihood of gaining optimal asthma control. Beta2-blockers are commonly prescribed for …

OBJECTIVE: To review the more recent literature addressing the issue of whether β2-
agonists can worsen asthma and/or increase the risk of severe exacerbations and death …

In an unusual paradox, asthmatics who are chronically treated with bronchodilating β-
agonists sometimes experience a worsening of their condition. A new study describes one …

An endogenous defect in β 2-adrenoceptors that results in impaired relaxation of airway
smooth muscle was originally proposed as a putative underlying cause of the asthmatic …

The β-adrenoceptor agonists (β-agonists) have been used to relieve bronchoconstriction for
at least 5000 years. β-agonists are based on adrenaline and early forms, such as …

BACKGROUND Despite widespread use of adrenergic agents in the management of
asthma for many decades, doubts have emerged concerning the safety and efficacy of long …

The decision by the Food and Drug Administration to issue a “black box” warning for long-
acting β-agonists has been followed by a series of pharmacoepidemiological studies …

Asthma ranks among the most common of chronic diseases in the Western world. Although
modern therapy has improved patient care, asthma still affects 5–10% of the population and …